Uncategorized files

Showing below up to 50 results in range #44,951 to #45,000.

• 
  Orchidometr.png 361 × 225; 26 KB
  
• 
  Orciprenaline ball-and-stick.png 800 × 546; 104 KB
  
• 
  Orciprenaline skeletal.png 1,024 × 622; 16 KB
  
• 
  Orciprenaline skeletal svg.png 800 × 486; 12 KB
  
• 
  Order of changes in ovary svg.png 700 × 580; 107 KB
  
• 
  Orf goat kid.jpg 400 × 300; 86 KB
  
• 
  Orf virus.jpg 700 × 932; 90 KB
  
• 
  Orf virus infection on thumb.jpg 189 × 189; 5 KB
  
• 
  OrganSystems.jpg 630 × 630; 214 KB
  
• 
  Organic disulfide.png 365 × 122; 7 KB
  
• 
  Organoaxial-volvulus-001.jpg 600 × 600; 52 KB
  
• 
  Organoaxial-volvulus-002.jpg 600 × 600; 53 KB
  
• 
  Organoaxial-volvulus-101.jpg 713 × 700; 58 KB
  
• 
  Organoaxial-volvulus-102.jpg 694 × 700; 84 KB
  
• 
  Organoaxial-volvulus-103.jpg 685 × 700; 73 KB
  
• 
  Organoaxial-volvulus-104.jpg 700 × 525; 55 KB
  
• 
  Organocatalytic1.gif 394 × 122; 3 KB
  
• 
  Organocatalytic2.gif 598 × 274; 10 KB
  
• 
  Organocatalytic3.gif 622 × 106; 5 KB
  
• 
  Organocatalytic4.gif 694 × 374; 15 KB
  
• 
  Organocatalytic5.gif 651 × 570; 20 KB
  
• 
  Orientation.PNG 393 × 438; 186 KB
  
• 
  Orientation.png 393 × 438; 186 KB
  
• 
  Orientia tsutsugamushi.JPG 768 × 600; 176 KB
  
• 
  Original-blalock-taussig-shunt-creative-commons.png 597 × 469; 282 KB
  
• 
  Original.00005792-201101000-00001.F1-1.jpg 1,200 × 375; 91 KB
  
• 
  Original Geneva Conventions.jpg 2,048 × 1,536; 1.1 MB
  
• 
  Original antigenic sin.png 562 × 600; 47 KB
  
• 
  Original implant.jpg 180 × 347; 21 KB
  
• 
  Oritavancin 400 mg.png 622 × 240; 173 KB
  
• 
  Oritavancin Adverse reactions.png 623 × 738; 73 KB
  
• 
  Oritavancin Chemical structure.png 406 × 352; 72 KB
  
• 
  Oritavancin Clinical Response Rates in ABSSSI Trials using Reduction in Lesion Area of 20% or Greater at 48-72 Hours after Initiation of Therapy.png 618 × 329; 50 KB
  
• 
  Oritavancin Clinical Response Rates in ABSSSI Trials using Responders at 48-72 Hours after Initiation of Therapy.png 620 × 388; 56 KB
  
• 
  Oritavancin Clinical Success Rates in ABSSSI Trials at the Follow-Up Visit.png 625 × 427; 59 KB
  
• 
  Oritavancin FDA package label.png 622 × 1,494; 130 KB
  
• 
  Oritavancin Mean PK parameters.png 583 × 408; 48 KB
  
• 
  Oritavancin Outcomes by Baseline Pathogen.png 626 × 1,130; 140 KB
  
• 
  Oritavancin Population Mean Plasma Concentration.png 613 × 433; 81 KB
  
• 
  Oritavancin structure.png 265 × 200; 11 KB
  
• 
  Orlistat.png 800 × 601; 16 KB
  
• Error creating thumbnail: File missing
  Orlistat.svg 1,065 × 800; 5 KB
  
• 
  Orlistat3Dan.gif 256 × 256; 407 KB
  
• 
  Orlistat 3D sticks.png 1,000 × 424; 74 KB
  
• 
  Orlistat fig01.png 726 × 556; 146 KB
  
• 
  Orlistat fig02.png 752 × 597; 196 KB
  
• 
  Orlistat fig03.png 756 × 468; 217 KB
  
• 
  Orlistat patient information.png 729 × 5,297; 1.19 MB
  
• 
  Orlistat structure.png 700 × 237; 31 KB
  
• 
  Orlistat table01.png 757 × 410; 421 KB